1. Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer
- Author
-
Ledermann, Jonathan, Harter, Philipp, Gourley, Charlie, Friedlander, Michael, Vergote, Ignace, Rustin, Gordon, Scott, Clare L., Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Fielding, Anitra, Spencer, Stuart, Dougherty, Brian, Orr, Maria, Hodgson, Darren, Barrett, J. Carl, and Matulonis, Ursula
- Abstract
Greater than 20 of cases of high-grade serous ovarian cancer are due to germline or somatically acquired BRCAmutations. Poly(ADP-ribose) polymerase inhibitors have been investigated as treatment for a number of tumors, including those due to BRCAmutations. One potent oral poly(ADP-ribose) polymerase inhibitor, olaparib, has shown antitumor activity in patients with both BRCAand sporadic high-grade serous ovarian cancer. A previous randomized, double-blind, placebo-controlled phase 2 study showed that twice-daily maintenance treatment with oral olaparib in patients with platinum-sensitive recurrent serous ovarian cancer significantly improved progression-free survival (PFS). Subgroup analysis suggested that olaparib may increase PFS longer in patients with known BRCA status than in those with unknown mutation status.
- Published
- 2014
- Full Text
- View/download PDF